MX2009002756A - Composiciones farmaceuticas para la administracion oral o rectal de sustancias proteinicas. - Google Patents

Composiciones farmaceuticas para la administracion oral o rectal de sustancias proteinicas.

Info

Publication number
MX2009002756A
MX2009002756A MX2009002756A MX2009002756A MX2009002756A MX 2009002756 A MX2009002756 A MX 2009002756A MX 2009002756 A MX2009002756 A MX 2009002756A MX 2009002756 A MX2009002756 A MX 2009002756A MX 2009002756 A MX2009002756 A MX 2009002756A
Authority
MX
Mexico
Prior art keywords
oral
pharmaceutical compositions
rectal administration
protein
peptide
Prior art date
Application number
MX2009002756A
Other languages
English (en)
Spanish (es)
Inventor
Mauro Ajani
Original Assignee
Cosmo Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITMI20061741 external-priority patent/ITMI20061741A1/it
Priority claimed from ITMI20071205 external-priority patent/ITMI20071205A1/it
Application filed by Cosmo Technologies Ltd filed Critical Cosmo Technologies Ltd
Publication of MX2009002756A publication Critical patent/MX2009002756A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2009002756A 2006-09-12 2007-09-07 Composiciones farmaceuticas para la administracion oral o rectal de sustancias proteinicas. MX2009002756A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI20061741 ITMI20061741A1 (it) 2006-09-12 2006-09-12 Composizioni farmaceutiche per la somministrazione orale di sostanze proteiche
ITMI20071205 ITMI20071205A1 (it) 2007-06-15 2007-06-15 Composizioni farmaceutiche per la somministrazione orale o rettale di sostanze proteiche
PCT/EP2007/059378 WO2008031770A2 (en) 2006-09-12 2007-09-07 Pharmaceutical compositions for the oral or rectal administration of protein substances

Publications (1)

Publication Number Publication Date
MX2009002756A true MX2009002756A (es) 2009-05-25

Family

ID=39107203

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009002756A MX2009002756A (es) 2006-09-12 2007-09-07 Composiciones farmaceuticas para la administracion oral o rectal de sustancias proteinicas.

Country Status (8)

Country Link
US (1) US20100004157A1 (https=)
EP (1) EP2081555A2 (https=)
JP (1) JP2010502759A (https=)
KR (1) KR20090086060A (https=)
CA (1) CA2663548A1 (https=)
MX (1) MX2009002756A (https=)
RU (1) RU2009113557A (https=)
WO (1) WO2008031770A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12203056B2 (en) 2008-03-28 2025-01-21 Ecolab Usa Inc. Sulfoperoxycarboxylic acids, their preparation and methods of use as bleaching and antimicrobial agents
US8809392B2 (en) 2008-03-28 2014-08-19 Ecolab Usa Inc. Sulfoperoxycarboxylic acids, their preparation and methods of use as bleaching and antimicrobial agents
GB201017048D0 (en) * 2010-10-08 2010-11-24 Ucl Business Plc Composition
US10946091B2 (en) * 2012-06-04 2021-03-16 Gaurav Agrawal Compositions and methods for treating Crohn's disease and related conditions and infections
US10220076B2 (en) * 2014-05-15 2019-03-05 Incube Labs, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising glucose regulating proteins
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10689460B2 (en) 2014-05-15 2020-06-23 Incube Labs, Llc PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
SG11201706840WA (en) 2015-03-31 2017-09-28 Vhsquared Ltd Peptide construct having a protease-cleavable linker
CN113546036A (zh) * 2015-05-01 2021-10-26 拉尼医疗有限公司 药物组合物和用于制备包含多肽和/或蛋白质的固体块的方法
EP3294273A4 (en) * 2015-05-08 2018-12-05 Incube Labs, LLC Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
SG11201807402PA (en) * 2016-03-31 2018-09-27 Vhsquared Ltd Compositions
US11491114B2 (en) 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
EP3554541B1 (en) * 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
EP3501503A1 (en) 2017-12-22 2019-06-26 Cosmo Technologies Ltd. Solid delivery composition
KR20220063148A (ko) 2019-06-21 2022-05-17 소리소 파마슈티컬스 인크. 조성물
US12559552B2 (en) 2019-06-21 2026-02-24 Sorriso Pharmaceuticals, Inc. IL-23 and TNF-alpha binding bi-specific heavy chain polypeptides
CA3144567A1 (en) 2019-06-21 2020-12-24 Scott Crowe Polypeptides

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
JPH10503179A (ja) * 1994-06-24 1998-03-24 イミュネックス・コーポレーション 放出制御性ポリペプチド組成物および炎症性腸疾患の治療方法
CA2377301C (en) * 1999-06-14 2009-05-12 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions
EP1487457A1 (en) * 2001-11-30 2004-12-22 Pfizer Products Inc. Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
ITMI20012599A1 (it) * 2001-12-11 2003-06-11 Cosmo Spa Composizioni farmaceutiche per la somministrazione orale di eparina osuoi derivati, utili per la terapia di malattie infiammatorie dell'int
US8389008B2 (en) * 2003-09-19 2013-03-05 Penwest Pharmaceuticals Co. Delayed release dosage forms
EP2422804A1 (en) * 2004-06-17 2012-02-29 Amano Enzyme USA., Ltd. Controlled release formulations of enzymes, microorganisms, and antibodies with mucoadhesive polymers
US7879361B2 (en) * 2005-01-04 2011-02-01 Gp Medical, Inc. Nanoparticles for drug delivery
UA95235C2 (en) * 2005-05-04 2011-07-25 Зииланд Фарма А/С Glucagon-like-peptide-2 (glp-2) analogues

Also Published As

Publication number Publication date
CA2663548A1 (en) 2008-03-20
US20100004157A1 (en) 2010-01-07
KR20090086060A (ko) 2009-08-10
WO2008031770A2 (en) 2008-03-20
RU2009113557A (ru) 2010-10-20
JP2010502759A (ja) 2010-01-28
EP2081555A2 (en) 2009-07-29
WO2008031770A3 (en) 2008-09-12

Similar Documents

Publication Publication Date Title
MX2009002756A (es) Composiciones farmaceuticas para la administracion oral o rectal de sustancias proteinicas.
Gameiro et al. The influence of drugs and systemic factors on orthodontic tooth movement
FR23C1024I2 (fr) Composition stable d'une protéine anabolique osseuse qui est un analogue de pthrp, et ses emplois
ES2590454T3 (es) Hidrolizado de proteínas de pescado con actividad saciante, composiciones nutracéuticas y farmacológicas que comprenden tal hidrolizado y procedimiento de obtención
WO2003099225A3 (en) Compositions for delivering nucleic acids to cells
EP2583976A3 (en) Peptide vaccines with SEQ ID NO: 210, 196, 202, 213, 214, 214 or 223 for cancers expressing tumor-associated antigens
ATE482694T1 (de) Zusammensetzung zur kontrollierten wirkstoffabgabe
MX2009004519A (es) Sustancias que inhiben la glucolisis en un cultivo de celulas.
ZA200803350B (en) Method of acting upon organism by targeted delivery of biologically active substances into mitochondria, pharmaceutical composition for carrying out said method, and compound used for the purpose
EP3895699A3 (en) Pharmaceutical compositions comprising iron oxy-hydroxide
WO2015176031A3 (en) Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
AU2011247984A1 (en) Method of engrafting cells from solid tissues
CL2011001984A1 (es) Composicion seca estabilizadora para material biologico que comprende carbohidrato, proteinas hidrolizadas de animal o de planta y un componente de acido carboxilico; metodo de preparacion; y formulacion de entrega oral que comprende la composicion seca estabilizadora.
WO2006105173A3 (en) Oral delivery vehicle and material
WO2004069203A3 (en) Oral compositions of fenretinide having increased bioavailability and methods of using the same
UA72915C2 (uk) Поживна ентеральна композиція, призначена для підтримки зростання та дозрівання недорозвинених шлунково-кишкових трактів у молодих ссавців та її застосування
EP3252068A3 (en) Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
Li et al. Injectable bioadhesive hydrogels scavenging ROS and restoring mucosal barrier for enhanced ulcerative colitis therapy
EP1839499A4 (en) COMPOSITION OF HIGHLY DISPERSIBLE CELLULOSE COMPLEX AND POLYSACCHARIDE
IL173965A (en) Peptide compounds, pharmaceutical preparations containing them, uses and methods in vitro and ex vivo to activate a thrombopoietin receptor in the cell
Luke Translating 2A research into practice
TR200101929T2 (tr) Geliştirilmiş kararlılığa sahip bileşimler.
WO2006122914A3 (fr) Medicament notamment anti-cancereux, destine a des traitements par immunotherapie, en particulier autologue
Baral et al. Antiestrogens sensitize human ovarian and lung carcinomas for lysis by autologous killer cells
UA97496C2 (ru) Композиция укорененных мицеллярных наночастичек и способ ее получения

Legal Events

Date Code Title Description
FA Abandonment or withdrawal